<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093132</url>
  </required_header>
  <id_info>
    <org_study_id>SAT1-04-02</org_study_id>
    <nct_id>NCT00093132</nct_id>
  </id_info>
  <brief_title>Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy</brief_title>
  <official_title>A Phase 1/2 Study With Satraplatin and Simultaneous Radiation in Locally Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agennix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agennix</source>
  <brief_summary>
    <textblock>
      PURPOSE: This trial is designed to compare the combination of the investigational oral&#xD;
      cytotoxic drug, satraplatin, and radiation therapy for patients with locally advanced&#xD;
      Non-Small Cell Lung Cancer (NSCLC) with no prior chemotherapy or radiation therapy treatment.&#xD;
      Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria.&#xD;
&#xD;
      WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member&#xD;
      of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically&#xD;
      proven to be one of the most effective classes of anticancer therapies. Unlike the currently&#xD;
      marketed platinum-based drugs, satraplatin can be given orally.&#xD;
&#xD;
      RATIONALE: Intravenously administered platinum-based drugs are currently used in combination&#xD;
      with radiation therapy in the treatment of patients with locally advanced NSCLC. The purpose&#xD;
      of this Phase I trial is to determine a tolerable dose and schedule for the oral platinum&#xD;
      drug (satraplatin) when given to NSCLC patients throughout the course of their radiotherapy&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decided to discontinue study drug development.&#xD;
  </why_stopped>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of MTD and recommended dose for phase II trials</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Carcinoma, Non-small Cell Lung</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Satraplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Satraplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Satraplatin</intervention_name>
    <description>Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.</description>
    <arm_group_label>Satraplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced or medically inoperable NSCLC (stage II or III)&#xD;
&#xD;
          -  ECOG performance status score 0-2&#xD;
&#xD;
          -  Adequate bone marrow, liver, and pulmonary functions&#xD;
&#xD;
          -  Life expectancy &gt; three months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior malignancy&#xD;
&#xD;
          -  Serious concurrent uncontrolled medical disorder.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  History of mastectomy&#xD;
&#xD;
          -  Pregnant or breast-feeding patients are not eligible&#xD;
&#xD;
          -  Prior radiotherapy to the primary tumor site or cytotoxic chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>October 1, 2004</study_first_submitted>
  <study_first_submitted_qc>October 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2004</study_first_posted>
  <disposition_first_submitted>August 9, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 9, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 17, 2012</disposition_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer (stage II or III)</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Squamous Cell Lung Cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>carcinoma, non-small cell lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Satraplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

